Immunophenotyping analyses already suggested that these drugs could eliminate bulk blast cells without eradicating leukaemia stem and progenitor cells in AML patients42 and did not correct CD34+ cell immunophenotypic aberrancies in CMML patients43. The gene discussed is CD34; the disease is chronic myelomonocytic leukemia.